BetterLife Pharma (BETRF) Income towards Parent Company (2016 - 2026)
BetterLife Pharma (BETRF) posted quarterly Income towards Parent Company of -$444456.7 for Q2 2026, down 197.56% year-over-year from $455579.4 in Q2 2025, and down 23.5% quarter-over-quarter from -$359872.4 in Q3 2025.
BetterLife Pharma (BETRF) Income towards Parent Company (2016 - 2026) Analysis & Trends
BetterLife Pharma's Income towards Parent Company history runs 11 years deep, the most recent figure standing at -$444456.7 for Q2 2026.
- In Q2 2026, Income towards Parent Company fell 197.56% year-over-year to -$444456.7; the TTM figure through Apr 2026 stood at -$953696.8 (up 24.17% YoY), while the FY2026 annual figure was -$1.1 million, up 56.54% from the prior year.
- Income towards Parent Company for Q2 2026 stood at -$444456.7, down from -$359872.4 in the prior quarter.
- The five-year high for Income towards Parent Company was $6.5 million in Q1 2022, with the low at -$3.2 million in Q4 2022.
- The 5-year median for Income towards Parent Company is -$471341.5 (2026), against an average of -$381406.6.
- Peak annual rise in Income towards Parent Company reached 366.67% in 2024, while the deepest fall reached 412.26% in 2024.
- BetterLife Pharma's Income towards Parent Company stood at -$3.2 million in 2022, then jumped by 94.9% to -$165447.2 in 2023, then soared by 366.67% to $441202.5 in 2024, then plunged by 181.57% to -$359872.4 in 2025, then decreased by 23.5% to -$444456.7 in 2026.
- Business Quant data shows BETRF's Income towards Parent Company at -$444456.7 in Q2 2026, -$359872.4 in Q3 2025, and -$149367.8 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | BetterLife Pharma | 36.45 Mn | 36.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -444,456.65 |
| Jul 31, 2025 | -359,872.38 |
| Apr 30, 2025 | -149,367.79 |
| Jan 31, 2025 | -498,226.32 |
| Oct 31, 2024 | 441,202.48 |
| Jul 31, 2024 | -1.05 Mn |
| Apr 30, 2024 | -1.46 Mn |
| Jan 31, 2024 | -943,557.65 |
| Oct 31, 2023 | -165,447.17 |
| Jul 31, 2023 | -763,669.43 |
| Apr 30, 2023 | -284,564.97 |
| Jan 31, 2023 | -436,357.32 |
| Oct 31, 2022 | -3.24 Mn |
| Jul 31, 2022 | -880,362.09 |
| Apr 30, 2022 | -2.36 Mn |
| Jan 31, 2022 | 6.50 Mn |
| Oct 31, 2021 | -1.76 Mn |
| Jul 31, 2021 | -2.91 Mn |
| Apr 30, 2021 | -1.87 Mn |
| Jan 31, 2021 | -21.23 Mn |